 |
|
Patients Homozygous and Heterozygous for SNCA Duplication in a Family With Parkinsonism and Dementia
Takeshi Ikeuchi, MD, PhD;
Akiyoshi Kakita, MD;
Atsushi Shiga, MS;
Kensaku Kasuga, MD;
Hiryoyuki Kaneko, MS;
Chun-Feng Tan, MD;
Jiro Idezuka, MD;
Koichi Wakabayashi, MD;
Osamu Onodera, MD;
Takeshi Iwatsubo, MD;
Masatoyo Nishizawa, MD;
Hitoshi Takahashi, MD;
Atsushi Ishikawa, MD
Arch Neurol. 2008;65(4):514-519.
Background Multiplication of the  -synuclein gene (SNCA) (OMIM 163890) has been identified as a causative mutation in hereditary Parkinson disease or dementia with Lewy bodies.
Objective To determine the genetic, biochemical, and neuropathologic characteristics of patients with autopsy-confirmed autosomal dominant Lewy body disease, with particular reference to the dosage effects of SNCA.
Design Four-generation family study.
Setting Academic research.
Patients We fractionated samples extracted from frozen brain tissues of 4 patients for biochemical characterization, followed by immunoblot analysis.
Main Outcome Measures We determined the dosages of SNCA and its surrounding genes by quantitative polymerase chain reaction analysis.
Results Quantitative polymerase chain reaction analysis revealed that 3 patients were heterozygous for SNCA duplication and 1 patient was homozygous for SNCA duplication. The homozygous patient showed earlier age at onset and earlier death, with more severe cognitive impairment than the heterozygous patients. Biochemical analysis revealed that phosphorylated -synuclein accumulated in the sarkosyl-insoluble urea-extracted fraction of the brains of the patients.
Conclusions Pathologically confirmed Lewy body disease clinically characterized by progressive parkinsonism and cognitive dysfunction is caused by SNCA duplication. The homozygous patient demonstrated the most severe phenotype, suggesting that SNCA dosage has a considerable effect on disease phenotype even within a family. SNCA duplication results in the hyperaccumulation of phosphorylated -synuclein in the brains of patients.
Author Affiliations: Departments of Molecular Neuroscience (Drs Ikeuchi, Kasuga, and Onodera and Messrs Shiga and Kaneko), Pathology Neuroscience (Dr Kakita), Pathology (Drs Tan and Takahashi), and Neurology (Messrs Shiga and Kaneko and Drs Kasuga and Nishizawa), Brain Research Institute, Niigata University, Department of Neurology, Ojiya-Sakura Hospital (Dr Idezuka), and Department of Neurology, Nishi-Ojiya National Hospital, and Department of Neurology, Brain Disease Center, Agano Hospital (Dr Ishikawa), Niigata; Japan Department of Neuropathology, Hirosaki University School of Medicine, Hirosaki (Dr Wakabayashi); and Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo (Dr Iwatsubo); Japan.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease
Kasuga et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:1050-1052.
ABSTRACT
| FULL TEXT
Parkinson's disease: from monogenic forms to genetic susceptibility factors
Lesage and Brice
Hum Mol Genet 2009;18:R48-R59.
ABSTRACT
| FULL TEXT
Phosphorylation does not prompt, nor prevent, the formation of {alpha}-synuclein toxic species in a rat model of Parkinson's disease
Azeredo da Silveira et al.
Hum Mol Genet 2009;18:872-887.
ABSTRACT
| FULL TEXT
PROMINENT PSYCHIATRIC SYMPTOMS AND GLUCOSE HYPOMETABOLISM IN A FAMILY WITH A SNCA DUPLICATION
Uchiyama et al.
Neurology 2008;71:1289-1291.
FULL TEXT
|
